Search Results

You are looking at 111 - 120 of 595 items for :

  • "surveillance" x
Clear All
Full access

Philip W. Kantoff and James L. Mohler

overall survival benefit in metastatic castration-resistant prostate cancer (mCRPC). Treatment Versus Active Surveillance James L. Mohler, MD, Chair of the NCCN Panel on Prostate Cancer, discussed 4 areas of controversy in prostate cancer in

Full access

Nishant Patel, Adam C. Yopp and Amit G. Singal

rates near 70% with resection or liver transplantation, whereas those with advanced HCC have a median survival of less than 1 year. 2 Surveillance at 6-month intervals is recommended in patients with cirrhosis and is associated with improved early

Full access

Joseph J. Fantony and Brant A. Inman

Bladder cancer is the second most common malignancy of the genitourinary tract and fifth most common malignancy overall in the United States. 1 The current standard for diagnosis and surveillance of bladder cancer includes a combination of

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer and Rashmi Kumar

experience relapse. To prevent relapse in patients with stages IA and IB pure seminoma, the standard management options after initial orchiectomy include active surveillance, RT, or chemotherapy with 1 or 2 cycles of carboplatin. The disease-specific survival

Full access

James L. Mohler

spawned new interest in active surveillance as an option for the management of clinically localized prostate cancer. In 2009, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer were the first cancer guidelines to

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang and Richard B. Wilder

after initial orchiectomy include surveillance, radiotherapy, or chemotherapy with 1 or 2 cycles of carboplatin. The disease-specific survival for stage I disease is 99%, irrespective of the management strategy used. 16 Several prospective nonrandomized

Full access

Anne M. Covey

In an Italian study that compared 6- and 12-month surveillance, 15 the researchers found that 6-month surveillance increased detection of HCC amenable to curative treatment and improved OS (45 vs 30 months, respectively). Ability to Treat Once

Full access

a new algorithm. OSTEO-4 Under “Surveillance”: 6th bullet was modified to include “Orthopedic and Oncologic.” BONE-A Under “Core Group”: “Musculoskeletal oncologist” was added and “surgical oncologist” was omitted

Full access

Peter A. Ubel

surveillance, surgery, and radiotherapy. Each option has pros and cons, which are weighed differently by different patients. In brief, Dr. Ubel noted, the conversation with the patient could go something like, “You can have a surveillance strategy that

Full access

Gold Standard for Prostate Cancer Care Kawachi Mark H. MD 08 2007 5 5 7 7 689 689 692 692 0050689 10.6004/jnccn.2007.0059 Point: Active Surveillance for Favorable Risk Prostate Cancer Klotz Laurence MD, FRCSC 08 2007 5 5 7 7 693